Product Description
Derazantinib (formerly ARQ 087) is an investigational orally administered small-molecule panFGFR kinase inhibitor with strong activity against FGFR1, 2, and 3.5 FGFR kinases are key drivers of cell proliferation, differentiation and migration.
Mechanisms of Action: FGFR2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Basilea Pharmaceutica
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Ireland, Italy, Korea, Poland, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Cholangiocarcinoma|Hepatocellular Carcinoma|Transitional Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2020-004938-38 | P2 |
Active, not recruiting |
Cholangiocarcinoma |
2025-12-08 |
|
| 2019-000359-15 | P2 |
Active, not recruiting |
Transitional Cell Carcinoma |
2022-11-08 |
|
| FIDES-01 | P2 |
Completed |
Hepatocellular Carcinoma|Cholangiocarcinoma |
2022-10-25 |
|
| FIDES-02 | P2 |
Completed |
Transitional Cell Carcinoma |
2022-10-04 |